The renal vascular effects of prostaglandin Ej (PGEj), 6-keto-PCE,, and PGL> were investigated in indomethacin-pretreated rats. These prostanoids were infused directly into the left renal artery at rates ranging from 0.01 to 1.0 /ig/min, while renal blood flow and mean arterial blood pressure were constantly monitored. PGE^, 6-keto-PCEi, and PGIj produced reductions in mean arterial blood pressure with threshold doses of 1.0, 0.3, and 0.03 ;ig/min (P < 0.01), respectively, and maximal vasodepressor responses of 18.9 ± 4.3, 37.0 ± 7.8, and 58.7 ± 8.2 mm Hg (P < 0.01), respectively. In addition, all three prostanoids caused a dose-related reduction in renal vascular resistance with a threshold dose of 0.01 /xg/min (P < 0.05). The maximal reductions in renal vascular resistance were 2.59 ± 0.52, 4.41 ± 1.20, and 5.29 ± 1.06 mm Hg/(ml per min) for PGEj, 6-keto-PGEi, and PGI 2 (P < 0.01), respectively. Whereas PGE2 and 6-keto-PGEi produced dose-dependent increases in renal blood flow (maximal increases of 1.5 ± 0.3 and 1.0 ± 0.3 ml/min, respectively (P < 0.01), PGI 2 nonsignificantly increased renal blood flow at low doses and decreased renal blood flow at higher infusion rates (P< 0.01). These data indicate that the in vivo rat kidney, similar to the kidneys of other species, is vasodilated by low doses of PGE2, PGI2, and 6-keto-PGEi. (Ore Res 51:  67-72, 1982) 
PROSTAGLANDIN E, (PGE 2 ) is abundantly synthesized by renal tissue (Whorton et al., 1978; Hassid et al., 1979; Sraer et al., 1979) . Furthermore, recent studies indicate that PGE.> may participate in several physiological mechanisms in the kidney (Anderson et al., 1976; Dunn and Hood, 1977; Franco-Saenz et al., 1980) , as well as in the response of the kidney to drugs (Attallah, 1979; Campbell and Zimmer, 1981) and pathophysiological states (Isakson et al., 1977; Tan et al., 1978; Dunn et al., 1978; Suzuki et al., 1980) . Delineation of the precise involvement of PGE 2 in renal physiological, pathophysiological, and pharmacological mechanisms requires an understanding of the actions of intrarenally formed PGE 2 on kidney function in the in vivo situation.
With respect to the effects of PGE 2 on the renal vasculature, an important species difference apparently exists. In the rabbit, dog, and cat, PGE 2 vasodilates the renal vasculature (Malik and McGiff, 1975; Chang et al., 1975; Chapnick et al., 1976) and inhibits renal adrenergic neurotransmission (Lonigro et al., 1973; Frame and Hedqvist, 1975; Chapnick et al., 1976) . In contrast, in vitro PGE 2 constricts the rat kidney and facilitates adrenergic neurotransmission (Malik and McGiff, 1975) . Even when administered to the rat in vivo into either the abdominal aorta or the left ventricle of the heart (Gerber and Neis, 1979) , PGE 2 produces renal vasoconstriction. Therefore, based upon current knowledge, involvement of PGE 2 in renal mechanisms in the rat must be quite different from that in other species.
However, for several reasons, previous investiga-tions of the renal effects of PGE2 in the rat kidney might not have reflected the true effects of intrarenally formed PGE 2 on the renal vasculature in vivo. First, basal prostaglandin production was not suppressed by cyclooxygenase inhibition before dose-response curves to exogenous prostaglandins were determined. As discussed by Horrobin (1977) , this becomes particularly important when examining the effects of prostaglandins that might exhibit bell-shaped doseresponse curves. Second, the most convincing vasoconstrictor responses to PGE 2 were demonstrated in the isolated, artificially perfused rat kidney preparation (Malik and McGiff, 1975) . As previously documented with histamine (Campbell and Itskovitz, 1976) , the artificially perfused kidney may respond quite differently from the blood-perfused kidney. Third, for those studies conducted in vivo, the prostaglandins were administered into either the suprarenal abdominal aorta or the left ventricle of the heart (Gerber and Nies, 1979) , rather than directly into the renal artery. Since these approaches resulted in marked hemodynamic changes, the direct renal effects of the infused prostaglandins might have been obscured by reflex sympathetic renal vasoconstriction due to the systemic hypotension, or by the action of other vasoconstrictors such as angiotensin II. Since knowledge concerning the vascular effect of PGE-2 in the rat is prerequisite to understanding the involvement of PGE 2 in renal processes in this species, we decided to investigate further the vascular effects of PGE 2 in the rat kidney. In these studies, PGE 2 and-for comparison-PGI 2 and 6-keto-PGEi, were infused over a 100-fold dose range directly into the renal artery of indomethacin-pretreated animals, while renal blood flow was constantly monitored with an electromagnetic flow probe. Our studies indicate that, like other species, the rat renal vasculature is dilated by these prostaglandins.
Methods
Male Wistar rats (400-500 g) obtained from Harlan Labs were used in all experiments. Rats were maintained on a diet of Wayne Lab-Blox containing 170 mEq Na/kg and 246 mEq K/kg and were given tap water ad libitum. Under pentobarbital anaesthesia (50 mg/kg, ip), the trachea was cannulated and polyethylene cannulae (PE50) were inserted into the left femoral artery and vein. Body temperature was maintained at 37°C by a thermostatically controlled heating pad (Yellow Springs Instrument Co.) connected to a rectal temperature monitor. A noncannulating electromagnetic flow probe (Statham Instruments) 1.0 mm in diameter was positioned around the left renal artery for renal blood flow (RBF) measurements. The electromagnetic flow probe was electronically zeroed, and the renal artery was momentarily occluded to validate the electronic balancing. Mean arterial blood pressure (MABP) was measured from the femoral artery line via a Hewlett-Packard pressure transducer and was recorded on a Hewlett-Packard Physiograph (model 7768A). A 30-gauge needle connected to a section of Silastic tubing was carefully inserted into the aorta so that the tip of the needle was positioned approximately 1-2 mm into the left renal artery. An intrarenal 0.9% saline infusion (80 ju.l/min) to maintain patency of the renal cannula then was begun, as was a supplementary infusion of 0.9% saline (40 /xl/min) into the femoral vein. Finally, the abdomen was covered with saline-moistened gauze, and indomethacin (10 mg/kg) suspended in olive oil was administered subcutaneously.
Thirty minutes after the indomethacin treatment, a cumulative dose-response curve to either PGE^, PGI a , or 6keto-PCEi was obtained by infusing either 0 (vehicle), 0.01, 0.03, 0.1, 0.3, or 1 fig/min of the prostanoids into the renal artery for 5 minutes at each dose (infusion rate was 80 ju.1/ min). For statistical comparisons, the RBF and MABP were recorded 5 minutes into each infusion. In order to avoid treatment interactions, only a single dose-response curve to a single prostaglandin was performed in each rat. To evaluate the effect of vehicle (glycine buffer) alone on renal resistance, in three rats vehicle only was infused throughout the treatment period (i.e., 30 minutes).
Stock solutions of PGE 2 , 6-keto-PGE,, and PCI. (2 mg/ ml) were stored in ethanol, acetone, and ethanol saturated with Na 2 CC>3, respectively, at -20°C. Immediately before the experiment, a small volume of these stock solutions was appropriately diluted in a glycine-NaCl buffer (pH 10.6) and placed on ice.
All values are expressed as the mean ± SEM. The doseresponse curves for each prostaglandin were analyzed by a model III 2-factor analysis of variance without replication in which the random factor was the animal and the fixed factor the dose (Zar, 1974) . A Dunnett's test for multiple comparisons to a control was then used to determine which doses produced statistically significant changes in MABP, RBF, or renal resistance. A P value of <0.05 was used as the criterion of significance.
Results
The baseline values for MABP, RBF, and renal resistance of each treatment group are in Table 1 . As Circulation Research/Vol. 51, No. ljuly 1982 shown in Figure 1 , when infused intrarenally, all three prostaglandins elicited a dose-dependent reduction in MABP with the order of potency being PGI2 > 6keto-PGE, > PGE 2 . Although PGI 2 lowered MABP at doses as low as 0.03 /xg/min, neither PGE2 nor 6-keto-PGE] significantly altered MABP until the dosage was increased to 1.0 and 0.3 yu,g/min, respectively. Both PGE2 and 6-keto-PGE, produced significant increases in RBF at doses >0.03 jug/min, while PGI2 caused a nonsignificant increase in RBF at low doses and a significant reduction of RBF at the highest dose (Fig.  2) . A representative tracing depicting the time course of PGE2-induced increases in RBF is shown in Figure  3 . Each prostanoid reduced renal vascular resistance (Fig. 4) , and the reduction in renal resistance was significant at doses as low as 0.01 jug/min. Assuming that 1.0 jug/min produced a near-maximal decline in renal resistance for each prostanoid, PGE2, PGI2, and 6-keto-PGEi produced half-maximal effects with infusion rates of 20, 23, and 47 ng/min, respectively. Although PGIa and 6-keto-PGEi elicited similar maximal changes in renal resistance (-5.29 ± 1.06 vs. -4.41 ± 1.20 mm Hg/(ml per min), the maximal vasodilatory response to PGE2 was somewhat less (-2.59 ± 0.52 mm Hg/(ml per min), P < 0.05, when compared to PGI2 maximal response). It is important to recognize that both PGE2 and 6-keto-PGEi produced increases in RBF and reductions in resistance with doses that did not affect MABP. On the other hand, the doses of PGI2 required to reduce renal resistance also reduced MABP.
It is possible that pretreatment of the animals with indomethacin qualitatively changed the renal vascular response to exogenous PGE2. To determine whether or not this was the case, we obtained a cumulative dose-response curve to exogenous PGE2 in four different rats not pretreated with indomethacin. As shown in Table 2 , in these animals PGE2 significantly increased renal blood flow and decreased renal vascular resistance, without significantly affecting mean arterial blood pressure.
The glycine buffer alone, when infused over the entire time couse of the experiment, had no affect on MABP (Fig. 1 ), but caused a decline in RBF (Fig. 2) and, therefore, an increase in renal resistance (Fig. 3 ). Since the buffer increased renal resistance, the decreases in renal resistance produced by infusions of the prostanoids were not due to a vehicle or time effect.
Discussion
These studies indicate that, when infused intrarenally in vivo at doses ranging from 0.01 to 1.0 jiig/ min, PGE2, PGI2, and 6-keto-PGEi are vasodilators in the rat kidney. This would suggest, therefore, that the direct vascular response of the in vivo rat kidney to prostaglandins is qualitatively similar to the response observed in other species.
These data are in contrast to earlier evidence which indicates that, unlike other species, the rat kidney is vasoconstricted by exogenous PGE2. In the isolated, artificially perfused rat kidney, PGE2 is unquestiona- bly a vasoconstrictor (Malik and McGiff, 1975) . However, the in vitro response of a tissue to an agent does not always mimic the in vivo response of the tissue. For instance, Campbell and Itskovitz (1976) noted that histamine vasoconstricted the isolated Krebs'-perfused dog kidney, but vasodilated the blood-perfused dog kidney. Furthermore, Jackson and Campbell (1980) found that PGE2 inhibited the vasoconstrictor response to adrenergic stimuli when infused into the superior mesenteric artery of the in vivo rat mesentery, yet enhanced the same stimuli in the isolated artificially perfused rat mesentery. Therefore, the vasoconstrictor responses of the isolated rat kidney to PGE2 may not reflect the responses of the in vivo rat kidney to PGE 2 . In addition, since the isolated, perfused rat kidney may exhibit little intrinsic vascular tone, a vasodilatory action of PGEa may go unnoticed in this preparation. Indeed, Rosenthal and Pace-Asciak (1980) noted that, in isolated rat kidneys constricted with either vasopressin, norepinephrine, or angiotensin II, low doses of PGE2 produced prolonged vasodilatation, whereas PGE2 increased vascular resistance in nonconstricted kidneys. Recently, and Gerber and Nies (1979) examined the influence of PGE2 on rat renal resistance in vivo. In the former study, PGE 2 was infused into the aorta at doses ranging from 2-20 /xg/min. These investigators reported that doses of PGE2 ranging from 4 to 20 /ig/min increase renal vascular resistance. However, since the PGE2 infusions also produced a concomitant decline in blood pressure, reflex changes in sympathetic tone or the release of vasoconstrictor hormones could have masked any vasodilatory response. Indeed, in this same study, similarly hypotensive doses of PGI2 failed to alter renal vascular resistance. Gerber and Nies (1979) , using a radioactive microsphere technique, demonstrated that left ventricular bolus injections of PGEo produced renal vasoconstriction, a response which was unaffected by ganglionic blockade with hexamethonium. These investigators concluded that PGE2 is a direct renal vasoconstrictor. However, the possibility of production or release of vasoconstrictors other than catecholamines, such as angiotensin II, was not eliminated. In addition, in this study only a single dose of PGE2 was used.
In contrast to these earlier reports, our studies indicate that low dose intrarenal infusions of PGE2 decrease renal vascular resistance. The major technical differences between our study and the aforementioned reports were: (1) the site of prostaglandin infusion (i.e., intrarenal vs. nonintrarenal), (2) the doses of PGE 2 (0.01-1.0 jttg/min vs. 2-20 jug/min), and (3) pretreatment of the animals with a cyclooxygenase inhibitor.
The intrarenal site of PGE2 administration allowed assessment of the renal vascular effects of PGEo at doses which did not produce systemic hemodynamic changes. Along these lines, it is particularly relevant to note that doses of PGE 2 ranging from 0.01 to 0.3 jiig/min significantly altered RBF and renal vascular resistance without affecting MABP. Therefore, the decrease in renal resistance induced by PGE2 at these doses was neither significantly attenuated by reflex sympathetic activity nor accentuated by renal autoregulatory processes.
Although in this investigation we limited the dose of PGE2 to 1.0 jug/min, in several pilot studies we attempted to infuse 3.0 jug/min of PGEj into the rat kidney. We found that the animals became hemodynamically unstable and the renal responses were quite variable i.e., some kidneys constricted, while others dilated. However, even though our contention that PGE2 is a renal vasodilator in the rat kidney applies only to infusion rates of <1.0 /j.g/min, it is unlikely that the effects of higher infusion rates would be biologically relevant. Even our highest dose of 1.0 fig/ min would mimic a renal PGE2 production rate of 2.88 mg/day (1.0 jug/min per kidney X 1440 min per day X 2 kidneys), which is approximately 27,000 times the daily renal excretion rate of PGE2 in the rat (Campbell et al., 1979) . Pretreatment of the racs with indomethacin allowed ( 6 r assessment of the renal vascular effects of PGE.) during suppression of endogenous PGE^ production. This approach allowed construction of a dose-response curve to exogenous PGE2 starting at a baseline of near zero concentration of prostaglandins in the biophase. This is important in that, if the concentrations of endogenous prostaglandins in the biophase are high, the addition of exogenous prostaglandins may produce no further effect, or in some situations a response opposite to that produced by biologically relevant concentrations of the prostaglandins. However, we infused PGE 2 into the renal artery of rats not pretreated with indomethacin and noted changes in RBF, MABP, and renal resistance that were qualitatively similar to those changes observed in indomethacin-treated animals. Therefore, in retrospect, pre- Values indicate mean ± SEM (n = 4). * P < 0.05 compared to control (2 way-ANOV); t P < 0.01 compared to control (2 way-ANOV).
treatment of the animals with indomethacin in this study was probably an unnecessary, yet logical, precaution.
Like PGE 2 , we found PGI 2 and 6-keto-PGE, also to be potent renal vasodilators in the rat. These results are in accord with previously published studies Quilley et al., 1979) , although the decreases in renal vascular resistance induced by PGI2 and 6-keto-PGEi reported previously were somewhat smaller. Interestingly, in an earlier report we found that in the nonfiltering, j3adrenoreceptor-blocked dog kidney, 6-keto-PGEi was more potent than PGI2 as a renal vasodilator (Jackson et al., 1981) . In the current study, we found PGI2 and 6-keto-PGEi to be approximately equipotent. However, unlike 6-keto-PGEi and PGEv, the renal vasodi-Iatory and systemic vasodepressor effects of PGI2 could not be separated. That is to say, any dose of PGI L > that produced a decline in renal resistance also caused systemic hypotension. Therefore, it is difficult to estimate what percentage of the decline in renal resistance induced by PGI2 was autoregulatory in origin, what percentage was the result of a direct effect of PGI2 on the renal vasculature, and to what extent the renal vasodilation was attenuated by reflex activation of the sympatho-adrenal axis.
In conclusion, PGE2, PGIa, and 6-keto-PGEi when infused intrarenally at doses ranging from 0.01 to 1.0 /ig/min are potent vasodilators of the in vivo rat kidney. This would suggest that the in vivo production of these prostanoids within the kidney of the rat might participate in renal mechanisms which produce a decrease in renal vascular tone.
